IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035

Best Price Guarantee	Publisher	Published Date	SKU
from $4,900	BIS Research	May, 2025	BIS20012715

Best Price Guarantee
Price	from $4,900
Publisher	BIS Research
Published Date	May, 2025
SKU	BIS20012715

Market Lifecycle Stage

The global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. The market is expanding as novel therapies, such as complement inhibitors and non-immunosuppressive drugs, are gaining traction, addressing the unmet need for more effective renal treatments. With ongoing research and development, pharmaceutical companies are investing heavily in clinical trials to bring new, targeted therapies to market. Additionally, regulatory bodies are accelerating the approval process for innovative renal drugs, further fueling market growth. Despite this positive momentum, challenges such as high treatment costs and the variability in disease progression may hinder rapid expansion. As a result, the market is expected to continue growing, although competition and price pressures will likely intensify as more treatments emerge.

Impact

Increasing demand for IgA nephropathy therapies is anticipated to support the growth of the global IgA nephropathy market during the forecast period 2025-2035.
The global IgA nephropathy market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

North America is expected to dominate the global IgA nephropathy market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global IgA nephropathy market.

Recent Developments

Regulatory Activities: In April 2025, the U.S. FDA granted accelerated approval for Novartis’ Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy.
Partnerships: In March 2025, Folia Health and Novartis Pharmaceuticals, Inc. announced their collaboration on an innovative at-home observational real-world evidence initiative aimed at supporting individuals with IgA nephropathy.
Regulatory Activities: In November 2024, South Korea approved Everest Medicines' NEFECON for the treatment of primary IgA nephropathy.
Regulatory Activities: In September 2024, Ligand partner Travere Therapeutics received FDA approval for FILSPARI (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy.

Demand – Drivers and Limitations

Drivers:

Increasing Prevalence of IgA Nephropathy
Continuous Advancements in Treatment Options
Improved Diagnosis and Awareness

Challenges:

High Treatment Costs
Limited Awareness in Developing Markets

How Can This Report Add Value to an Organization?

Product/Innovation Strategy:Product launches and innovations in the global IgA nephropathy market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Novartis, and Travere Therapeutics, Inc., have been involved in the development of therapies for IgA nephropathy.

Competitive Strategy:Enterprises led by market leaders in the global IgA nephropathy market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Novartis
F. Hoffmann-La Roche
Ionis Pharmaceuticals
Vertex Pharmaceuticals
Otsuka Pharmaceutical
Biogen
Arrowhead Pharmaceuticals
NovelMed
Q32 Bio
Walden Biosciences
Takeda Pharmaceutical
Vera Therapeutics
Biocity Biopharmaceutics Co., Ltd.
Calliditas Therapeutics AB
Travere Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Executive Summary: Scope of Study
1. Global IgA Nephropathy Market: Market Outlook: 1.1 Industry Outlook; 1.1.1 Market Overview and Ecosystem; 1.1.2 Market Trends; 1.1.3 Epidemiological Analysis of IgA Nephropathy; 1.1.3.1 By Region; 1.1.3.1.1 U.S.; 1.1.3.1.2 EU5; 1.1.3.1.3 Rest-of-the-World; 1.1.4 Clinical Trials; 1.1.4.1 By Phase; 1.1.4.2 By Sponsor Type; 1.1.5 Regulatory Landscape / Compliance; 1.1.5.1 Legal Requirement and Framework in the U.S.; 1.1.5.2 Legal Requirement and Framework in the E.U.; 1.1.5.3 Legal Requirement and Framework in Asia-Pacific; 1.1.5.4 Legal Requirement and Framework in Rest-of-the-World; 1.2 Market Dynamics; 1.2.1 Impact Analysis; 1.2.2 Market Drivers; 1.2.3 Market Restraints; 1.2.4 Market Opportunities
2. Global IgA Nephropathy Market (By Region), $Million, 2023-2035: 2.1 North America; 2.1.1 Key Findings; 2.1.2 Market Dynamics; 2.1.3 Market Sizing and Forecast; 2.1.3.1 North America IgA Nephropathy Market (by Country); 2.1.3.1.1 U.S.; 2.1.3.1.2 Canada; 2.2 Europe; 2.2.1 Key Findings; 2.2.2 Market Dynamics; 2.2.3 Market Sizing and Forecast; 2.2.3.1 Europe IgA Nephropathy Market (by Country); 2.2.3.1.1 U.K.; 2.2.3.1.2 Germany; 2.2.3.1.3 France; 2.2.3.1.4 Italy; 2.2.3.1.5 Spain; 2.2.3.1.6 Rest-of-Europe; 2.3 Asia-Pacific; 2.3.1 Key Findings; 2.3.2 Market Dynamics; 2.3.3 Market Sizing and Forecast; 2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country); 2.3.3.1.1 Japan; 2.3.3.1.2 China; 2.3.3.1.3 Rest-of-Asia-Pacific; 2.4 Rest-of-the-World; 2.4.1 Key Findings; 2.4.2 Market Dynamics; 2.4.3 Market Sizing and Forecast
3. Global IgA Nephropathy Market - Competitive Benchmarking and Company Profiles: 3.1 Competitive Landscape; 3.1.1 Key Strategies and Developments by Company; 3.1.1.1 Funding Activities; 3.1.1.2 Mergers and Acquisitions; 3.1.1.3 Regulatory Approvals; 3.1.1.4 Partnerships, Collaborations and Business Expansions; 3.1.2 Key Developments Analysis; 3.2 Company Profiles; 3.2.1 Novartis; 3.2.1.1 Company Overview; 3.2.1.2 Product Portfolio; 3.2.1.3 Target Customers/End Users; 3.2.1.4 Analyst View; 3.2.2 F. Hoffmann-La Roche; 3.2.2.1 Company Overview; 3.2.2.2 Product Portfolio; 3.2.2.3 Target Customers/End Users; 3.2.2.4 Analyst View; 3.2.3 Ionis Pharmaceuticals; 3.2.3.1 Company Overview; 3.2.3.2 Product Portfolio; 3.2.3.3 Target Customers/End Users; 3.2.3.4 Analyst View; 3.2.4 Vertex Pharmaceuticals; 3.2.4.1 Company Overview; 3.2.4.2 Product Portfolio; 3.2.4.3 Target Customers/End Users; 3.2.4.4 Analyst View; 3.2.5 Otsuka Pharmaceutical; 3.2.5.1 Company Overview; 3.2.5.2 Product Portfolio; 3.2.5.3 Target Customers/End Users; 3.2.5.4 Analyst View; 3.2.6 Biogen; 3.2.6.1 Company Overview; 3.2.6.2 Product Portfolio; 3.2.6.3 Target Customers/End Users; 3.2.6.4 Analyst View; 3.2.7 Arrowhead Pharmaceuticals; 3.2.7.1 Company Overview; 3.2.7.2 Product Portfolio; 3.2.7.3 Target Customers/End Users; 3.2.7.4 Analyst View; 3.2.8 NovelMed; 3.2.8.1 Company Overview; 3.2.8.2 Product Portfolio; 3.2.8.3 Target Customers/End Users; 3.2.8.4 Analyst View; 3.2.9 Q32 Bio; 3.2.9.1 Company Overview; 3.2.9.2 Product Portfolio; 3.2.9.3 Target Customers/End Users; 3.2.9.4 Analyst View; 3.2.10 Takeda Pharmaceutical; 3.2.10.1 Company Overview; 3.2.10.2 Product Portfolio; 3.2.10.3 Target Customers/End Users; 3.2.10.4 Analyst View; 3.2.11 Vera Therapeutics; 3.2.11.1 Company Overview; 3.2.11.2 Product Portfolio; 3.2.11.3 Target Customers/End Users; 3.2.11.4 Analyst View; 3.2.12 Biocity Biopharmaceutics Co., Ltd.; 3.2.12.1 Company Overview; 3.2.12.2 Product Portfolio; 3.2.12.3 Target Customers/End Users; 3.2.12.4 Analyst View; 3.2.13 Calliditas Therapeutics AB; 3.2.13.1 Company Overview; 3.2.13.2 Product Portfolio; 3.2.13.3 Target Customers/End Users; 3.2.13.4 Analyst View; 3.2.14 Travere Therapeutics, Inc.; 3.2.14.1 Company Overview; 3.2.14.2 Product Portfolio; 3.2.14.3 Target Customers/End Users; 3.2.14.4 Analyst View; 3.2.15 Alexion Pharmaceuticals, Inc.; 3.2.15.1 Company Overview; 3.2.15.2 Product Portfolio; 3.2.15.3 Target Customers/End Users; 3.2.15.4 Analyst View
4. Research Methodology
List of Figures: Figure: Global IgA Nephropathy Market, Market Overview; Figure: Global IgA Nephropathy Market, Epidemiological Analysis, U.S.; Figure: Global IgA Nephropathy Market Coverage; Figure: Global IgA Nephropathy Market Key Trends, Impact Analysis, 2023-2035; Figure: Global IgA Nephropathy Market, Competitive Landscape, January 2022-April 2025
List of Tables: Table: Global IgA Nephropathy Market, Regulatory Scenario; Table: Global IgA Nephropathy Market Dynamics, Impact Analysis